Mizuho Wants "to Get More Constructive" on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharma (VRX) AdCom on Brodalumab Begins
July 19, 2016 8:10 AM EDTValeant Pharma (NYSE: VRX) FDA advisory committee meeting for Brodalumab is starting now. Click here to access the webcast.
For the Brodalumab briefing docs, click here.
Shares of Valeant are lower in early trading Tuesday.
... MoreValeant (VRX) Scripts Plunge Amid 4-Day Week
July 18, 2016 10:16 AM EDTRBC Capital analyst Douglas Miehm notes Valeant Pharmaceuticals (NYSE: VRX) scripts fell following a four-day week (July 4th): Derm NRx were down 29.4% WoW and ophth NRx were down 19.1%.
NRx Derm products down 29.4% WoW. For the week ending July 8th, new derm scripts (NRx) were down 29.4% vs. up 0.9% the prior week due to a four-day week... More
